Biosynex Balance Sheet Health
Financial Health criteria checks 1/6
Biosynex has a total shareholder equity of €103.2M and total debt of €61.5M, which brings its debt-to-equity ratio to 59.6%. Its total assets and total liabilities are €208.8M and €105.5M respectively.
Key information
59.6%
Debt to equity ratio
€61.51m
Debt
| Interest coverage ratio | n/a |
| Cash | €10.74m |
| Equity | €103.21m |
| Total liabilities | €105.54m |
| Total assets | €208.75m |
Recent financial health updates
Biosynex (EPA:ALBIO) Could Easily Take On More Debt
Jun 23
We Think Biosynex (EPA:ALBIO) Can Stay On Top Of Its Debt
Dec 19Recent updates
Benign Growth For Biosynex SA (EPA:ALBIO) Underpins Stock's 27% Plummet
Oct 30Biosynex SA's (EPA:ALBIO) Shares Bounce 28% But Its Business Still Trails The Industry
Aug 16Biosynex SA (EPA:ALBIO) Not Doing Enough For Some Investors As Its Shares Slump 30%
Jun 29Biosynex SA (EPA:ALBIO) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Mar 12Biosynex SA's (EPA:ALBIO) Shares Not Telling The Full Story
Jan 20Returns On Capital Are Showing Encouraging Signs At Biosynex (EPA:ALBIO)
May 05Investors Shouldn't Overlook Biosynex's (EPA:ALBIO) Impressive Returns On Capital
Dec 01Biosynex (EPA:ALBIO) Could Easily Take On More Debt
Jun 23If You Like EPS Growth Then Check Out Biosynex (EPA:ALBIO) Before It's Too Late
Jul 11Here's Why I Think Biosynex (EPA:ALBIO) Is An Interesting Stock
Apr 06We Think Biosynex (EPA:ALBIO) Can Stay On Top Of Its Debt
Dec 19Financial Position Analysis
Short Term Liabilities: ALBIO's short term assets (€72.4M) do not cover its short term liabilities (€85.8M).
Long Term Liabilities: ALBIO's short term assets (€72.4M) exceed its long term liabilities (€19.7M).
Debt to Equity History and Analysis
Debt Level: ALBIO's net debt to equity ratio (49.2%) is considered high.
Reducing Debt: ALBIO's debt to equity ratio has increased from 14.6% to 59.6% over the past 5 years.
Debt Coverage: ALBIO's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: Insufficient data to determine if ALBIO's interest payments on its debt are well covered by EBIT.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 03:46 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Biosynex SA is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Laure Pédurand | EuroLand Corporate |